SAKK 16/14:围手术期度伐利尤单抗联合新辅助化疗治疗IIIA(N2)期非小细胞肺癌
主要终点1年EFS率达73%(90%CI 63-82),超过历史对照48%,MPR率62%,安全性可控。
要点
- 围手术期度伐利尤单抗联合新辅助化疗1年EFS率73%,高于历史化疗的48%。
- ≥3级不良事件发生率88%,两例致死性事件判定与治疗无关。
核心结论
- 围手术期度伐利尤单抗联合新辅助化疗在IIIA(N2)期非小细胞肺癌中安全,1年EFS率73%超过化疗历史数据,MPR率高。
研究设计与样本
- 新辅助治疗为3周期顺铂100 mg/m2联合多西他赛85 mg/m2每3周一次,序贯2剂度伐利尤单抗750 mg每2周一次,术后度伐利尤单抗继续1年。
- 主要终点为1年无事件生存率(EFS),统计假设为1年EFS从48%提升至65%。
主要发现
- 新辅助化疗后影像学缓解率43%(95%CI 31-56),序贯新辅助免疫治疗后为58%(95%CI 45-71)。
- 治疗前PD-L1表达对MPR或淋巴结降期无显著影响。
- 1年EFS率为73%(双侧90%CI 63-82),中位随访28.6个月时中位EFS和总生存均未达到。
临床怎么用
- 对于可切除IIIA(N2)期非小细胞肺癌,可考虑新辅助化疗后序贯围手术期度伐利尤单抗治疗。
- 该方案主要病理缓解率和1年EFS率令人鼓舞,但需关注高比例≥3级不良事件。
局限性
- 单臂II期设计,无同期随机对照,结论基于历史数据比较。
- 样本量较小(67例可分析),随访时间尚短,中位EFS和OS未达到。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: For patients with resectable stage IIIA(N2) non-small-cell lung cancer, neoadjuvant chemotherapy with cisplatin and docetaxel followed by surgery resulted in a 1-year event-free survival (EFS) rate of 48% in the SAKK 16/00 trial and is an accepted standard of care. We investigated the additional benefit of perioperative treatment with durvalumab. METHODS: Neoadjuvant treatment consisted of three cycles of cisplatin 100 mg/m2 and docetaxel 85 mg/m2 once every 3 weeks followed by two doses of durvalumab 750 mg once every 2 weeks. Durvalumab was continued for 1 year after surgery. The primary end point was 1-year EFS. The hypothesis for statistical considerations was an improvement of 1-year EFS from 48% to 65%. RESULTS: Sixty-eight patients were enrolled, 67 were included in the full analysis set. Radiographic response rate was 43% (95% CI, 31 to 56) after neoadjuvant chemotherapy and 58% (95% CI, 45 to 71) after sequential neoadjuvant immunotherapy. Fifty-five patients were resected, of which 34 (62%) achieved a major pathologic response (MPR; ≤ 10% viable tumor cells) and 10 (18%) among them a complete pathologic response. Postoperative nodal downstaging (ypN0-1) was observed in 37 patients (67%). Fifty-one (93%) resected patients had an R0 resection. There was no significant effect of pretreatment PD-L1 expression on MPR or nodal downstaging. The 1-year EFS rate was 73% (two-sided 90% CI, 63 to 82). Median EFS and overall survival were not reached after 28.6 months of median follow-up. Fifty-nine (88%) patients had an adverse event grade ≥ 3 including two fatal adverse events that were judged not to be treatment-related. CONCLUSION: The addition of perioperative durvalumab to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small-cell lung cancer is safe and exceeds historical data of chemotherapy alone with a high MPR and an encouraging 1-year EFS rate of 73%.
引用
- Rothschild SI, Zippelius A, Eboulet EI, et al. SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial. J Clin Oncol. 2021. PMID: 34251873. doi:10.1200/JCO.21.00276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。